title: [Simvastatin and extrinsic coagulation pathway in peritoneally dialyzed patients].
abstract: Peritoneally dialyzed subjects (CAPD) are prone to dyslipidemia and have a high risk of cardiovascular death. Statins (hydroxy-methylglutaryloCoA reductase inhibitors) show beneficial effects on serum lipids and hemostasis in kidney diseases. The purpose of this study was to assess platelet functions, some hemostatic parameters-extrinsic coagulation pathway-total, truncated, free TFPI (tissue factor pathway inhibitor), TF (tissue factor), TFPI/Xa and TF/VIIa complexes, as well as a marker of endothelial cell injury--von Willebrand factor--vWF and serum lipids in 10 hyperlipidemic CAPD patients treated with simvastatin (Zocor, MSD, at a dose of 10 mg at bedtime) for 3 months. Cholesterol and LDL fell significantly as early as after 1 month and remained lowered during further months of the therapy. No significant changes in von Willebrand factor, free TFPI, TF, TFPI/Xa and TF/VIIa complexes were found during therapy with simvastatin. Truncated TFPI decreased significantly as early as after 1 month and total TFPI decreased after 3 months of the therapy with simvastatin. Simvastatin is an effective hypolipemic agent. It seems that simvastatin have no or only little effect on endothelial function and extrinsic coagulation pathway in peritoneally dialyzed patients.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Małyszko
authors.forename: Jacek S
authors.initials: JS
authors.lastname: Małyszko
authors.forename: Tomasz
authors.initials: T
authors.lastname: Hryszko
authors.forename: Krystyna
authors.initials: K
authors.lastname: Pawlak
authors.forename: Michał
authors.initials: M
authors.lastname: Myśliwiec
mesh_terms: D000328:Adult; D000368:Aged; D001779:Blood Coagulation Factors / Q000187:drug effects* / Q000378:metabolism; D005167:Factor VII / Q000187:drug effects; D015951:Factor Xa / Q000187:drug effects; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008074:Lipoproteins / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D019821:Simvastatin / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D013997:Time Factors; D014841:von Willebrand Factor / Q000187:drug effects
chemical_list: D001779:Blood Coagulation Factors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D014841:von Willebrand Factor; D005167:Factor VII; D019821:Simvastatin; D015951:Factor Xa